Clinical determinants of immunotherapy outcomes in non-small cell lung cancer patients with checkpoint inhibitor pneumonitis
I. Vathiotis (Athens, Greece), K. Tavernaraki (Athens, Greece), I. Trontzas (Athens, Greece), E. Antonogiannaki (Athens, Greece), E. Koukaki (Athens, Greece), N. Syrigos (Athens, Greece), I. Gkiozos (Athens, Greece), E. Kotteas (Athens, Greece), A. Charpidou (Athens, Greece)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Vathiotis (Athens, Greece), K. Tavernaraki (Athens, Greece), I. Trontzas (Athens, Greece), E. Antonogiannaki (Athens, Greece), E. Koukaki (Athens, Greece), N. Syrigos (Athens, Greece), I. Gkiozos (Athens, Greece), E. Kotteas (Athens, Greece), A. Charpidou (Athens, Greece). Clinical determinants of immunotherapy outcomes in non-small cell lung cancer patients with checkpoint inhibitor pneumonitis. 1917
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|